Ketamine for Opioid Use Disorder

Randomised, quadruple-blind, parallel-group Phase II trial comparing IM ketamine (0.75 mg/kg, four doses over two weeks) with an active placebo (diphenhydramine 50 mg IM) in adults initiating methadone for opioid use disorder (n≈50).

Primary outcomes assess opioid craving and withdrawal symptoms; secondary outcomes include depression, pain, sleep quality, retention in methadone treatment, and safety assessed acutely and over 90 days of follow-up.